durvalumab,tremelimumab
astrazeneca,pfizer
['poseidon']
io/io combinations seem to best in squamous, low pd-l1, younger patients #esmo22 but poseidon doesn't support this, so not totally clear. 
Medical Oncologist, Translational Researcher, Peter Mac. Tweets are my own opinions. Musician (@mayhemtomi) https://t.co/f3ccD2Ml7v